These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7714978)

  • 1. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T
    Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study.
    Alfthan O; Andersson L; Esposti PL; Fosså SD; Gammelgaard PA; Gjöres JE; Isacson S; Rasmussen F; Ruutu M; von Schreeb T; Setterberg G; Strandell P; Strindberg B
    Scand J Urol Nephrol; 1983; 17(1):37-43. PubMed ID: 6346476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma.
    Agardh CD; Nilsson-Ehle P; Lundgren R; Gustafson A
    J Urol; 1984 Nov; 132(5):1021-4. PubMed ID: 6492270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P; Rasmussen F; Asmussen C; Christensen IJ; Eickhoff J; Klarskov P; Larsen E; Mogensen P; Mommsen S; Rosenkilde P
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.
    Andersson L; Berlin T; Boman J; Collste L; Edsmyr F; Esposti PL; Gustafsson H; Hedlund PO; Hultgren L; Leander G; Nordle O; Norlén H; Tillegård P
    Scand J Urol Nephrol Suppl; 1980; 55():143-5. PubMed ID: 6259722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
    J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of prostatic cancer: effects on serum lipoproteins and the cardiovascular system.
    Rössner S; Hedlund PO; Jogestrand T; Säwe U
    J Urol; 1985 Jan; 133(1):53-7. PubMed ID: 3964880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
    Noguchi M; Noda S; Yoshida M; Ueda S; Shiraishi T; Itoh K;
    Int J Urol; 2004 Feb; 11(2):103-9. PubMed ID: 14706014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients.
    Damber JE; Daehlin L; Tomic R; Nilsson TK
    Int Urol Nephrol; 1991; 23(3):251-6. PubMed ID: 1889971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of prostatic carcinoma with various types of estrogen derivatives.
    Jönsson G; Olsson AM; Luttrop W; Cekan Z; Purvis K; Diczfalusy E
    Vitam Horm; 1975; 33():351-76. PubMed ID: 1229063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer.
    Hoshi S; Yamaguchi O; Fujioka T; Arai Y; Tomita Y; Habuchi T; Ohyama C; Suzuki T; Orikasa S;
    Int J Clin Oncol; 2006 Aug; 11(4):303-8. PubMed ID: 16937304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L; Damber JE; von Schoultz B; Bergman B
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.